One of the major reasons for the high incidence of graft failure and GVHD in MHC matched unrelated marrow transplants is believed to be undetected microvariant mismatches of the MHC molecules. The overall goals of this proposal is to identify the undetected microvariants and to evaluate the impact of these mismatches on marrow transplants. From these studies, we plan to determine the acceptable limits of HLA incompatibility, and from there develop tissue typing strategies applicable to clinical HLA typing for patient-donor matching. To achieve these goals, this project is organized into two parts; studies focusing on structural polymorphism, with emphasis on the identification of microheterogeneity in class I molecules (specific aim 1) and studies focusing on the determination of the biological significance of those micro differences in inducing alloreactivity following marrow transplants (specific aim 2). A special emphasis is placed on the structural and functional characterization of the HLA-C molecules, whose allelic definition and functions are still unclear. The goal of specific aim 1 is to provide a fine definition of class I alleles and to develop a detection system to identify them. Direct sequencing and various PCR-based DNA typing methods (SSOP, SSCP, heteroduplex formation) will be used to provide the means for a retrospective evaluation of the phenotypically matched unrelated marrow transplanted pairs. The goal of specific aim 2 is to examine the biological significance of class I subtype mismatches in marrow transplants. Thus, the major focus of specific aim 2 is placed on the functional evaluation of the class I mismatches involving class I IEF variants or IEF undetectable microvariants on the induction of alloreactive cytolytic T cells and alloreactive NK cells. An in vitro system using transfectants that express a single class I allele will be employed to measure the CTL-p and NK-p frequencies in pairwise examination, and also to study the class I recognition motifs used by alloreactive CTLs and NK cells. Ultimately, the results will aid us in the development of strategies for the prospective typing of unrelated marrow donors and recipients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023766-19
Application #
5207046
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1996
Total Cost
Indirect Cost
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753

Showing the most recent 10 out of 452 publications